JP2011524339A5 - - Google Patents

Download PDF

Info

Publication number
JP2011524339A5
JP2011524339A5 JP2011509678A JP2011509678A JP2011524339A5 JP 2011524339 A5 JP2011524339 A5 JP 2011524339A5 JP 2011509678 A JP2011509678 A JP 2011509678A JP 2011509678 A JP2011509678 A JP 2011509678A JP 2011524339 A5 JP2011524339 A5 JP 2011524339A5
Authority
JP
Japan
Prior art keywords
antigen
cell
cancer
cancer cell
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011509678A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011524339A (ja
JP5779091B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/043874 external-priority patent/WO2009140447A1/en
Publication of JP2011524339A publication Critical patent/JP2011524339A/ja
Publication of JP2011524339A5 publication Critical patent/JP2011524339A5/ja
Application granted granted Critical
Publication of JP5779091B2 publication Critical patent/JP5779091B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011509678A 2008-05-16 2009-05-14 Ｉａｐ阻害剤による免疫調節 Active JP5779091B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5394708P 2008-05-16 2008-05-16
US61/053,947 2008-05-16
PCT/US2009/043874 WO2009140447A1 (en) 2008-05-16 2009-05-14 Immunomodulation by iap inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015040113A Division JP5986655B2 (ja) 2008-05-16 2015-03-02 Ｉａｐ阻害剤による免疫調節

Publications (3)

Publication Number Publication Date
JP2011524339A JP2011524339A (ja) 2011-09-01
JP2011524339A5 true JP2011524339A5 (https=) 2014-04-24
JP5779091B2 JP5779091B2 (ja) 2015-09-16

Family

ID=40823320

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011509678A Active JP5779091B2 (ja) 2008-05-16 2009-05-14 Ｉａｐ阻害剤による免疫調節
JP2015040113A Active JP5986655B2 (ja) 2008-05-16 2015-03-02 Ｉａｐ阻害剤による免疫調節
JP2015236482A Active JP6030739B2 (ja) 2008-05-16 2015-12-03 Ｉａｐ阻害剤による免疫調節

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2015040113A Active JP5986655B2 (ja) 2008-05-16 2015-03-02 Ｉａｐ阻害剤による免疫調節
JP2015236482A Active JP6030739B2 (ja) 2008-05-16 2015-12-03 Ｉａｐ阻害剤による免疫調節

Country Status (17)

Country Link
US (4) US9750729B2 (https=)
EP (3) EP2698158B1 (https=)
JP (3) JP5779091B2 (https=)
KR (1) KR20110022608A (https=)
CN (1) CN102099035A (https=)
AU (1) AU2009246347A1 (https=)
BR (1) BRPI0912692A2 (https=)
CA (1) CA2724720A1 (https=)
CL (1) CL2009001195A1 (https=)
EA (1) EA201071316A1 (https=)
ES (2) ES2882855T3 (https=)
IL (1) IL209203A0 (https=)
MA (1) MA32388B1 (https=)
MX (1) MX2010012231A (https=)
TW (1) TW201006834A (https=)
WO (1) WO2009140447A1 (https=)
ZA (1) ZA201008176B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
WO2007048224A1 (en) 2005-10-25 2007-05-03 Aegera Therapeutics Inc. Iap bir domain binding compounds
CN102099035A (zh) * 2008-05-16 2011-06-15 诺瓦提斯公司 Iap抑制剂的免疫调节
JP4995211B2 (ja) * 2008-09-29 2012-08-08 キヤノン株式会社 電子写真画像形成装置
US9284350B2 (en) 2010-02-12 2016-03-15 Pharmascience Inc. IAP BIR domain binding compounds
KR20160030099A (ko) * 2013-06-25 2016-03-16 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 세포내 감염의 치료 방법
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
AU2017253560B2 (en) * 2016-04-20 2019-03-21 Glaxosmithkline Intellectual Property Development Limited Conjugates comprising RIPK2 inhibitors
CN106496213B (zh) * 2016-09-30 2019-08-20 东南大学 Lcl161前药及其制备方法和应用
WO2020027225A1 (ja) * 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
CN113453678A (zh) 2018-11-26 2021-09-28 德彪药业国际股份公司 Hiv感染的联合治疗
PH12022550721A1 (en) 2019-09-25 2024-05-13 Debiopharm Int Sa Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2610934B1 (fr) * 1987-02-13 1989-05-05 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
ES2415336T3 (es) * 2003-04-11 2013-07-25 Survac Aps Vacuna terapéutica contra el cáncer
CN1938332B (zh) * 2004-02-04 2011-10-19 沃泰克斯药物股份有限公司 丝氨酸蛋白酶、特别是hcv ns3-ns4a蛋白酶的抑制剂
WO2005084317A2 (en) 2004-03-01 2005-09-15 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
AU2005228950B2 (en) * 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
DK2253614T3 (da) * 2004-04-07 2013-01-07 Novartis Ag IAP-inhibitorer
US20080234042A1 (en) 2004-05-02 2008-09-25 Hiroshi Uemura Game System
MX2007010371A (es) * 2005-02-25 2008-01-11 Tetralogic Pharmaceuticals Inhibidores dimericos iap.
KR20080080131A (ko) 2005-12-20 2008-09-02 노파르티스 아게 Ｉａｐ-억제제와 탁산의 조합물
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110220A1 (es) 2006-08-02 2011-04-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
WO2008045905A1 (en) 2006-10-12 2008-04-17 Novartis Ag Pyrrolydine derivatives as iap inhibitors
BRPI0717411A2 (pt) 2006-10-19 2013-11-12 Novartis Ag Uso de inibidores de iap
AU2007325280B2 (en) * 2006-11-28 2011-03-10 Dana-Farber Cancer Institute, Inc. Combination of IAP inhibitors and FLT3 inhibitors
EP2126188A1 (en) 2006-12-26 2009-12-02 Arçelik Anonim Sirketi A washer / dryer with output from humidity sensor selectively input to control unit
WO2008109057A1 (en) * 2007-03-02 2008-09-12 Dana-Farber Cancer Institute, Inc. Organic compounds and their uses
CN102099035A (zh) * 2008-05-16 2011-06-15 诺瓦提斯公司 Iap抑制剂的免疫调节

Similar Documents

Publication Publication Date Title
JP2011524339A5 (https=)
WO2014049447A3 (en) A whole, leech saliva extract
WO2016020856A3 (en) Immunological reagents binding to pd-1
EP3263128A3 (en) Compositions for immunising against staphylococcus aureus
PH12017500803A1 (en) Anti-pd-1 antibodies
AR083293A1 (es) Agentes de union a cd33
WO2017030823A3 (en) Anti-tigit antibodies
HK1249452A1 (zh) 免疫细胞捕获装置及其制备和使用方法
PE20061287A1 (es) COMPOSICION INMUNOGENICA QUE COMPRENDE gE VZV Y EL ADYUVANTE TH-1
WO2013039861A3 (en) Engineered nucleic acids and methods of use thereof
CL2016002004A1 (es) Anticuerpos anti-jagged1 y métodos de uso
MX2013001613A (es) Métodos y composiciones para prevenir una afección.
WO2014153056A8 (en) Cancer treatment using antibodies that bind cell surface grp78
NZ731103A (en) Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
WO2014197835A3 (en) Methods and compositions for the treatment of cancer
MX2016007903A (es) Metodos de elaboración de perfiles de epitopos de celulas t, elaboracion de composiciones de celulas t y tratamiento de enfermedades.
WO2016077789A8 (en) Neutralizing antibodies to ebola virus glycoprotein and their use
EP4233896A3 (en) Method for preparing an immunogenic lysate, the lysate obtained, dendritic cells loaded with such lysate and a pharmaceutical composition comprising the lysate or the dendritic cells
WO2017203370A3 (en) Cmv epitopes
HK1210475A1 (en) Herpes simplex virus vaccine
WO2017041092A3 (en) Anti-survivin antibodies for cancer therapy
EP3150632A3 (en) Anti-ricin antibodies and uses thereof
JP2010260831A5 (https=)
WO2014165164A3 (en) Compositions and methods for treating autoimmune diseases
MX2016000021A (es) Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn.